GSK 201000-A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis. (GLIMMER: GSK2330672 triaL of Ibat inhibition with Multidose Measurement for Evaluation of Response).
Investigator: Cynthia Levy
Institutional Protocol #: 20161080
National Clinical Trials Identifier: NCT02966834
Therapeutic Area: Liver Disease
Phase: Phase II
Enrolling Since: 1/11/2017